Method for Obtaining Primary Ovarian Cancer Cells From Solid Specimens
February 4th, 2014
This study describes a detailed method for isolation and characterization of primary ovarian cancer cells from solid clinical specimens. Ovarian cancer clinical specimens are subjected to enzymatic digestion to obtain viable, fibroblast-free epithelial ovarian cancer (EOC) cells highly suitable for downstream applications.
The overall goal of this procedure is to isolate and characterize primary ovarian cancer cells from solid clinical specimens. This is accomplished by first collecting the ovarian tumor specimen and placing it in a Petri dish. The second step is to cut the sample into pieces and transfer the pieces into a conical tube with digestion reagents for incubation.
Next, the cell slurry is run through a filter where only the cells are collected For centrifugation, the final step is to discard the supernatant and resuspend the cells in media for incubation overnight. Ultimately, the epithelial ovarian cancer cells will grow in culture for weeks, which allows for downstream applications. This method can help answer key questions in the ovarian cancer field, such as what the best treatment option is for each individual patient.
The implications of this technique extend toward the treatment of ovarian cancer because it allows us to use more realistic cell cultures, which are highly susceptible to genetic manipulation and are more useful for drug screening tests. To begin, supplement 500 milliliters of delcos, modified eagles, medium, or DMEM with 10%fetal bovine serum or FBS and 1%penicillin, streptomycin or ps. Store the medium at four degrees Celsius.
Collect the sample from the OR and transport it on ice to the lab still inside the transported container. Place the sample in a biological safety hood. Transfer the sample from a 50 milliliter conical tube onto a 60 millimeter by 60 millimeter Petri dish containing 10 milliliters of fresh ice cold PBS.
Next, using a sterile razor blade further, cut the sample into two millimeter or smaller pieces. Then treat DMEM with disc paste tube in a 15 liter conical tube. Transfer the minced tissues to the DMEM dispa two mixture tube.
Then incubate the sample at 5%carbon dioxide and 37 degrees Celsius for 30 minutes. Manually agitate the cell slurry every five minutes to ensure optimal digestion. After incubation, transfer cell slurry through a 70 micrometer mesh cell strainer placed on top of a 50 milliliter conical tube.
Gently apply pressure against the mesh using a syringe plunger, discard any unassociated tissue remaining on top of the mesh, and collect the obtained cell suspension in the 50 milliliter sterile conical tube. Next, centrifuge. The conical tube at 320 times G for seven minutes at four degrees Celsius.
Discard the supernatant and resuspend the cell pellet in 10 milliliters of DMEM containing 10%FBS and 1%ps. Then transfer the cell suspension to a Petri dish and incubate the suspension at 5%carbon dioxide and 37 degrees Celsius. Change the medium 24 hours after the initial plating to remove the cellular debris and the majority of the erythrocytes present in the culture.
Finally, change the medium every three days for the following two weeks after which the cultures of primary EOC cells are ready for downstream applications. Immediately after plating. The epithelial ovarian cancer cells or EOC cells appear as single cell suspensions and in clumps with erythrocytes and cell debris abound.
EOC cell culture three days after plating shows semi adherent EOC cell clusters and less erythrocyte contamination. One week after initial plating, the EOC cell culture becomes a swirl like cluster of cells spreading on the tissue culture plastic. The typical epithelial cobble stone morphology can be seen in a confluent monolayer of EOC cells after 14 days in culture.
After watching this video, you should have a good understanding of how to isolate and characterize primary ovarian cancer cells from solid clinical specimens.
View the full transcript and gain access to thousands of scientific videos
Overview
This study describes a detailed method for isolation and characterization of primary ovarian cancer cells from solid clinical specimens. The procedure allows for the growth of epithelial ovarian cancer cells in culture, facilitating downstream applications.
Key Study Components
Area of Science
- Oncology
- Cell Biology
- Clinical Research
Background
- Ovarian cancer is a significant health concern with complex treatment options.
- Isolation of viable cancer cells is crucial for personalized medicine.
- Current methods may not yield pure epithelial ovarian cancer cells.
- This study aims to improve the isolation process for better research outcomes.
Purpose of Study
- To isolate primary ovarian cancer cells from clinical specimens.
- To characterize the isolated cells for further applications.
- To enhance understanding of treatment options for ovarian cancer patients.
Methods Used
- Collection of ovarian tumor specimens.
- Enzymatic digestion of tissue samples.
- Filtration to isolate viable cells.
- Centrifugation and resuspension in media for culture.
Main Results
- Successful isolation of fibroblast-free epithelial ovarian cancer cells.
- Cells can be cultured for weeks, allowing for extensive study.
- The method provides a reliable source of cancer cells for research.
- Potential to inform personalized treatment strategies.
Conclusions
- The described method is effective for isolating ovarian cancer cells.
- It supports further research into ovarian cancer treatments.
- Future studies can build on this method to enhance patient outcomes.
Frequently Asked Questions
Executive Industry Relevance
Establishing primary ovarian cancer cells from solid clinical specimens enables patient-relevant models that reduce reliance on passaged cell lines with accumulated genetic artifacts. This approach supports mechanistic de-risking in target validation by preserving tumor heterogeneity and site-specific biology from primary or metastatic lesions. The resulting cultures provide a renewable source for downstream screening, improving predictive confidence in preclinical decision-making.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses using cells that reflect the original clinical specimen’s genetic and phenotypic profile.
- Operational Value: Reduces mechanistic ambiguity by avoiding artifacts associated with long-term passaged cell lines.
- Predictive Value: Supports portfolio triage through biologically de-risked target validation in a disease-relevant system.
Screening & Assay Development
- Scientific Value: Produces epithelial ovarian cancer cells suitable for drug screening with maintained tumorigenic properties.
- Operational Value: Delivers standardized, reproducible cell suspensions after enzymatic digestion and filtration.
- Scalability: Enables preparation of multiple primary cultures from diverse specimens for parallel assay testing.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical work by using cells derived directly from patient specimens.
- Biomarker Alignment: Supports evaluation of targets and biomarkers in a context reflective of the patient’s tumor.
- Risk-Adjusted Advancement: Informs go/no-go decisions based on responses in primary cells that better predict clinical outcomes.
Pipeline & Workflow Integration
The method fits within the discovery continuum from early biology to lead identification, providing primary cells that enhance the relevance of downstream screening and validation efforts.
- Discovery Biology: Supports hypothesis testing and pathway clarification using cells with intact tumor-specific characteristics.
- Screening: Delivers assay-ready primary epithelial ovarian cancer cells with quantifiable growth and morphology for compound evaluation.
- Analytics: Enables measurement of drug response, proliferation, and phenotypic changes in a genetically stable, low-passage system.
- Translational Research: Maintains clinical relevance through direct derivation from specimens, supporting biomarker and target validation.
- Enterprise Reuse: Establishes a reusable platform for generating primary cultures from varied specimens, reducing dependency on finite cell lines.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by using cells that mirror the heterogeneity and biology of the original tumor.
- Operational Value: Ensures reproducibility through standardized enzymatic digestion, filtration, and culture initiation steps.
- Strategic Value: Improves capital efficiency by reducing late-stage failure risk through better preclinical target validation.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on activity in patient-derived primary cells.
Implementation Considerations
- Requires expertise in sterile tissue handling, enzymatic digestion, and primary cell culture techniques.
- Depends on access to fresh or properly preserved ovarian tumor specimens collected under sterile conditions.
- Necessitates centrifugation, filtration, and culture equipment including biosafety hoods and CO2 incubators.
- Involves optimization of digestion time and mechanical dissociation to maximize epithelial yield while minimizing fibroblast contamination.
- Limited by specimen availability and viability, which may vary based on surgical timing and transport conditions.
